BG105302A - Means for improving cognition - Google Patents

Means for improving cognition

Info

Publication number
BG105302A
BG105302A BG105302A BG10530201A BG105302A BG 105302 A BG105302 A BG 105302A BG 105302 A BG105302 A BG 105302A BG 10530201 A BG10530201 A BG 10530201A BG 105302 A BG105302 A BG 105302A
Authority
BG
Bulgaria
Prior art keywords
improving cognition
acetylcholinesterase
alzheimer
inhibitor
administered
Prior art date
Application number
BG105302A
Other languages
Bulgarian (bg)
Inventor
NIJS Paul Leonce DE
Wim Louis PARYS
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG105302A publication Critical patent/BG105302A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to pharmaceutical compositions having synergetic effect in the treatment of patients suffering from Alzheimer's disease or related dementias, and can be administered for the prevention or reduction of adverse effects, associated with the application of one of the listed ingredients. The means includes an atypical antipsychotic agent, inhibitor of acetylcholinesterase and a suitable carrier. 14 claims
BG105302A 1998-10-16 2001-03-01 Means for improving cognition BG105302A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203454 1998-10-16
PCT/EP1999/007804 WO2000023057A2 (en) 1998-10-16 1999-10-12 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition

Publications (1)

Publication Number Publication Date
BG105302A true BG105302A (en) 2001-11-30

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105302A BG105302A (en) 1998-10-16 2001-03-01 Means for improving cognition

Country Status (20)

Country Link
EP (1) EP1121131A2 (en)
JP (1) JP2002527469A (en)
KR (1) KR20010072878A (en)
CN (1) CN1367697A (en)
AU (1) AU6472799A (en)
BG (1) BG105302A (en)
BR (1) BR9914419A (en)
CA (1) CA2345767A1 (en)
EE (1) EE200100136A (en)
HK (1) HK1039745A1 (en)
HR (1) HRP20010262A2 (en)
HU (1) HUP0103781A3 (en)
ID (1) ID28441A (en)
IL (1) IL142588A0 (en)
NO (1) NO20011403L (en)
PL (1) PL348107A1 (en)
SK (1) SK4592001A3 (en)
TR (1) TR200101082T2 (en)
WO (1) WO2000023057A2 (en)
ZA (1) ZA200103081B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
ES2358416T3 (en) 2001-10-30 2011-05-10 Novartis Ag PROLONGED RELEASE FORMATIONS OF ILOPERIDONE AND POLYMER IN THE FORM OF A STAR.
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
CA2552221A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
AU2004325725A1 (en) * 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5523107B2 (en) 2006-11-30 2014-06-18 プロビオドルグ エージー Novel inhibitors of glutaminyl cyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
MX2007008642A (en) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Pharmaceutical composition comprising the combination of a benzisoxazolic derived agent and a reversible inhibiting agent of the cholinesterase enzyme prescribed for the control and treatment of psychotic disorders and dementias.
US20110212928A1 (en) 2010-02-09 2011-09-01 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584185B1 (en) * 1991-05-14 1999-08-11 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DK1011678T3 (en) * 1997-08-11 2008-05-05 Univ South Florida Use of mecamylamine for the treatment of nicotine-responsive neuropsychiatric disorders
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders

Also Published As

Publication number Publication date
ZA200103081B (en) 2002-07-12
AU6472799A (en) 2000-05-08
ID28441A (en) 2001-05-24
HUP0103781A3 (en) 2003-09-29
WO2000023057A2 (en) 2000-04-27
HUP0103781A2 (en) 2002-03-28
CN1367697A (en) 2002-09-04
IL142588A0 (en) 2002-03-10
WO2000023057A3 (en) 2000-07-27
SK4592001A3 (en) 2001-12-03
CA2345767A1 (en) 2000-04-27
NO20011403D0 (en) 2001-03-20
JP2002527469A (en) 2002-08-27
PL348107A1 (en) 2002-05-06
KR20010072878A (en) 2001-07-31
NO20011403L (en) 2001-03-20
HK1039745A1 (en) 2002-05-10
EE200100136A (en) 2002-06-17
BR9914419A (en) 2001-06-26
HRP20010262A2 (en) 2002-06-30
EP1121131A2 (en) 2001-08-08
TR200101082T2 (en) 2001-09-21

Similar Documents

Publication Publication Date Title
BR0207961A (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases.
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
HK1039745A1 (en) Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition
BR0008059A (en) Compositions of valdecoxib
IL119989A0 (en) Pharmaceutical compositions for oral treatment of multiple sclerosis
EP1040830A4 (en) REMEDY FOR NEURODEGENERATIVE DISEASES
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
AU2002307049A1 (en) Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
BG105256A (en) Muscarinic agonists and antagonists
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
IL149134A0 (en) Pharmaceutical compositions containing tofisopam
IL124091A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
IL159241A0 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
MX9707642A (en) Pharmaceutical agents for the treatment of alzheimer's disease.
JO3446B1 (en) Method for treating primary insomnia
AU4568400A (en) Sphingomyelinase inhibitor
GEP20043377B (en) Pharmaceutical Complex
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
WO2002024727A3 (en) New inhibitors of iapp fibril formation and uses thereof
BR0005319A (en) Combined treatment for depression and anxiety